AZACTAM

This brand name is authorized in United States. It is also authorized in Austria, Finland, France, Ireland, Japan, Malta, New Zealand, Singapore, Spain, UK.

Active ingredients

The drug AZACTAM contains one active pharmaceutical ingredient (API):

1	Aztreonam UNII G2B4VE5GH8 - AZTREONAM
	Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, including P. aeruginosa. Aztreonam binds to penicillin-binding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis, followed by filamentation and cell lysis.
	Read more about Aztreonam

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AZACTAM Powder for solution for injection or infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DF01	Aztreonam	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DF Monobactams
Discover more medicines within J01DF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	57781
FI	Lääkealan turvallisuus- ja kehittämiskeskus	155960, 156042
FR	Base de données publique des médicaments	63918096
GB	Medicines & Healthcare Products Regulatory Agency	43437, 43441
JP	医薬品医療機器総合機構	6122400D1028, 6122400D2024
MT	Medicines Authority	AA565/56001, AA565/62202, AA565/62203, AA565/62204, AA565/62205, AA565/62206, AA565/62207
NZ	Medicines and Medical Devices Safety Authority	3735
SG	Health Sciences Authority	00556P
US	FDA, National Drug Code	0003-2560, 0003-2570